Unmet Need in CIDP Patients Treated With Immunoglobin: Results of a Multinational Real-World Survey
Author(s)
Clémence Arvin-Berod, Dr1, Swapna Karkare, MSc2, Febe Brackx, MSc3, Arash Mahajerin, Dr2, Dustin Nowacek, Dr2, Lucas Van de Veire, MA3, Rabiyah Sahar, MSc4, Yasmin Taylor, MBiol4, Jack Wright, MSc4, Jonathan James de Courcy, BSc4, Sarah Dewilde, PhD3.
1argenx BV, Ghent, Belgium, 2argenx US Inc., Boston, MA, USA, 3Services in Health Economics BV, Brussels, Belgium, 4Adelphi Real World, Bollington, United Kingdom.
1argenx BV, Ghent, Belgium, 2argenx US Inc., Boston, MA, USA, 3Services in Health Economics BV, Brussels, Belgium, 4Adelphi Real World, Bollington, United Kingdom.
Presentation Documents
OBJECTIVES: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a neurological disorder that causes weakness and sensory symptoms. This study seeks to characterize the real-world experience of CIDP patients treated with intravenous/subcutaneous immunoglobulin (IVIg/SCIg).
METHODS: This secondary analysis used matched data from patients prescribed IVIg/SCIg and their neurologists, collected through the Adelphi CIDP Disease Specific Programme™ (September 2022-April 2023). This real-world, cross-sectional survey captured demographics, treatment history and satisfaction, employment status and use of a caregiver and mobility aids across the US, UK, France, Germany, Italy, Spain and Japan.
RESULTS: Patients receiving IVIg/SCIg were 43% (108/251) of the total sample. Mean (SD) age was 54.3 (14.1) years and 59% (64/108) were male. Median (IQR) time since treatment had begun was 1.8 (0.8-3.7) years. The top patient-reported treatment goals were “regaining control/function of arms and/or legs” (33/105), “improving overall quality of life” (25/105) and “improving balance and co-ordination” (20/105).
Despite treatment, 47% (51/108) reported moderate-to-severe symptoms, including leg weakness (78/107), numbness (74/107), tingling sensations (67/107), loss of balance/falling (62/107) and difficulty walking (53/107). Half of physicians were very satisfied with the current regimen, compared to only 14% (14/98) of patients.
Nearly two-third (67/108) required mobility aids, most commonly a cane (35/67), shower chair (35/67), and support railings (34/67). A third (32/106) needed caregiver help, usually from a partner/spouse (27/32).
Of the patients who were retired (24/108), unemployed (14/108), on long term sick leave (11/108) or working part time (8/108), over half (28/53) cited CIDP as the cause. Of those employed, nearly a quarter (9/39) had missed time from work within the last 7 days due to CIDP (mean 10.6 hours).
CONCLUSIONS: There remains an unmet need in CIDP patients receiving IVIg/SCIg due to reduced productivity, a high need for mobility aids and some requiring caregiver help in daily life.
METHODS: This secondary analysis used matched data from patients prescribed IVIg/SCIg and their neurologists, collected through the Adelphi CIDP Disease Specific Programme™ (September 2022-April 2023). This real-world, cross-sectional survey captured demographics, treatment history and satisfaction, employment status and use of a caregiver and mobility aids across the US, UK, France, Germany, Italy, Spain and Japan.
RESULTS: Patients receiving IVIg/SCIg were 43% (108/251) of the total sample. Mean (SD) age was 54.3 (14.1) years and 59% (64/108) were male. Median (IQR) time since treatment had begun was 1.8 (0.8-3.7) years. The top patient-reported treatment goals were “regaining control/function of arms and/or legs” (33/105), “improving overall quality of life” (25/105) and “improving balance and co-ordination” (20/105).
Despite treatment, 47% (51/108) reported moderate-to-severe symptoms, including leg weakness (78/107), numbness (74/107), tingling sensations (67/107), loss of balance/falling (62/107) and difficulty walking (53/107). Half of physicians were very satisfied with the current regimen, compared to only 14% (14/98) of patients.
Nearly two-third (67/108) required mobility aids, most commonly a cane (35/67), shower chair (35/67), and support railings (34/67). A third (32/106) needed caregiver help, usually from a partner/spouse (27/32).
Of the patients who were retired (24/108), unemployed (14/108), on long term sick leave (11/108) or working part time (8/108), over half (28/53) cited CIDP as the cause. Of those employed, nearly a quarter (9/39) had missed time from work within the last 7 days due to CIDP (mean 10.6 hours).
CONCLUSIONS: There remains an unmet need in CIDP patients receiving IVIg/SCIg due to reduced productivity, a high need for mobility aids and some requiring caregiver help in daily life.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
RWD111
Topic
Real World Data & Information Systems
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, SDC: Neurological Disorders, SDC: Systemic Disorders/Conditions (Anesthesia, Auto-Immune Disorders (n.e.c.), Hematological Disorders (non-oncologic), Pain)